drugset
drugset / Trial / NCT05590936

Dimenydrinate vs Ondansetron for PONV (DONV)

NCT05590936 ↗

Completed 190 enrolled University of Thessaly
RandomizedParallel-groupTriple-blindPrevention

Summary

This study will investigate the impact of dimenydrinate (H1-receptor antagonist) versus ondansetron (HT3-receptor antagonist) in postoperative nausea and vomiting, in surgery-related preoperative stress and in the incidence of postoperative complications that could lengthen the LOS in PACU and/or the overall LOS.

Timeline

Start
2018-01-01
Primary completion
2022-12-07
Completion
2022-12-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dimenhydrinate Small molecule 50 mg Oral
Subject Ondansetron Other / unclassified 4 mg Intravenous

Indications

No indication recorded.